This technology is a multiplex, array-based serologic assay for the rapid diagnosis of tick-borne illnesses.
Current methods to diagnose tick-borne diseases (TBDs) consist of multi-step, labor-intensive laboratory methods that measure protein concentrations in serologic samples. However, these approaches are limited in accuracy and sensitivity, often leading to false positives and failing to diagnose early-stage tick-borne illnesses.
This technology, termed TBD-Serochip, is a programmable peptide microarray platform that can detect antigenic targets from prominent agents of tick-born diseases (TBDs) in a rapid and accurate manner. An array of up to 172,000 target peptides generates a comprehensive antigenic profile from the most prominent TBD agents. As such, this technology has the potential to streamline the diagnosis of TBDs through early detection of exposure to and/or infection by tick-borne pathogens.
This technology has been validated with human serum samples.
Patent Pending (US20200255889)
IR CU17323
Licensing Contact: Kristin Neuman